These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 7688919)
1. [Hematopoietic growth factors in antineoplastic therapy from the therapeutic and economic aspect]. Adam Z; Vorlícek J; Tomíska M Vnitr Lek; 1993 May; 39(5):487-500. PubMed ID: 7688919 [TBL] [Abstract][Full Text] [Related]
2. [Hematopoietic growth factors in the prevention of infections complications in children with hematologic-oncologic diseases]. Lehrnbecher T Klin Padiatr; 2001 Sep; 213 Suppl 1():A88-102. PubMed ID: 11577368 [TBL] [Abstract][Full Text] [Related]
3. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
4. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Bruserud O; Foss B; Petersen H Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510 [TBL] [Abstract][Full Text] [Related]
6. [Clinical use of hematopoietic growth factors in the treatment of acute myeloblastic leukemia]. Tóthová E Vnitr Lek; 1998 Jun; 44(6):373-7. PubMed ID: 9820064 [TBL] [Abstract][Full Text] [Related]
7. [Current status of the clinical application of hematopoietic growth factors in oncology]. Karthaus M; Ganser A Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692 [TBL] [Abstract][Full Text] [Related]
8. Haematopoietic growth factors as supportive therapy in HIV-infected patients. Hermans P AIDS; 1995 Dec; 9 Suppl 2():S9-S14. PubMed ID: 8775801 [TBL] [Abstract][Full Text] [Related]
9. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989 [TBL] [Abstract][Full Text] [Related]
10. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF]. Borota R; Borota J; Belić A; Gebauer E; Stefanović N Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690 [TBL] [Abstract][Full Text] [Related]
11. GM-CSF as an adjunct to autologous bone marrow transplantation. Gulati S; Bennett C; Phillips J; Van-Poznak C Stem Cells; 1993 Jan; 11(1):20-5. PubMed ID: 8457776 [TBL] [Abstract][Full Text] [Related]
12. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation. Barge AJ Bone Marrow Transplant; 1993; 11 Suppl 2():1-11. PubMed ID: 8334433 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic use of colony stimulating factors for established neutropenic fever. Walton SM W V Med J; 1998; 94(1):26-8. PubMed ID: 9505567 [TBL] [Abstract][Full Text] [Related]
14. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938 [TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470 [TBL] [Abstract][Full Text] [Related]
16. Cost considerations in therapy with myeloid growth factors. Glaspy JA; Jakway J Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789 [TBL] [Abstract][Full Text] [Related]
17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia. Weber RJ Clin Ther; 1993; 15(1):180-91; discussion 168. PubMed ID: 8458047 [TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713 [TBL] [Abstract][Full Text] [Related]
20. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]